This funding jointly led by Section 32 and Sanofi Ventures will enable our portfolio company Nucleai to expand its commercial footprint in biopharma and further develop its state of the art spatial biology platform.
Existing investors, including Debiopharm, Fosun RZ Capital, Vertex Ventures, and Grove Ventures, participated in this round.
Avi Veidman, CEO of Nuclai said:
Nucleai’s vision is to bring spatial biology to the forefront of precision medicine and to embed the use of our platform in every clinical trial involving tissue over the next few years
Access to their full press release here